| MeSH term | MeSH ID | Detail |
|---|---|---|
| Peptic Ulcer Perforation | D010439 | 3 associated lipids |
| Ureteral Diseases | D014515 | 3 associated lipids |
| Sporotrichosis | D013174 | 3 associated lipids |
| Hernia, Hiatal | D006551 | 3 associated lipids |
| Ecchymosis | D004438 | 3 associated lipids |
| Conjunctivitis, Bacterial | D003234 | 3 associated lipids |
| Keratoconjunctivitis | D007637 | 3 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Bartonella Infections | D001474 | 3 associated lipids |
| Paronychia | D010304 | 3 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jaup BH and Norrby A | Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7771426 |
| Pamuk ON et al. | Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? | 2000 | Am. J. Gastroenterol. | pmid:10926000 |
| Laine L et al. | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. | 2003 | Am. J. Gastroenterol. | pmid:12650788 |
| Take S et al. | Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. | 2003 | Am. J. Gastroenterol. | pmid:14638340 |
| de Bortoli N et al. | Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. | 2007 | Am. J. Gastroenterol. | pmid:17313499 |
| Mohar A et al. | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. | 2002 | Am. J. Gastroenterol. | pmid:12385434 |
| De Francesco V et al. | Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? | 2002 | Am. J. Gastroenterol. | pmid:12385470 |
| Savarino V et al. | What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? | 1995 | Am. J. Gastroenterol. | pmid:8540537 |
| Gisbert JP et al. | Response to article by Forné et al. | 1996 | Am. J. Gastroenterol. | pmid:8561132 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Cremonini F et al. | Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. | 2002 | Am. J. Gastroenterol. | pmid:12425542 |
| Peterson WL et al. | Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. | 1993 | Am. J. Gastroenterol. | pmid:8237933 |
| Sánchez-Delgado J et al. | Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. | 2008 | Am. J. Gastroenterol. | pmid:18564109 |
| Watson JB and Moss SF | Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. | 2011 | Am. J. Gastroenterol. | pmid:22056576 |
| Sapone A et al. | The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. | 2003 | Am. J. Gastroenterol. | pmid:12809821 |
| Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
| Suzuki S et al. | The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. | 2016 | Am. J. Gastroenterol. | pmid:27185079 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Vakil N et al. | Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. | 1998 | Am. J. Gastroenterol. | pmid:9732920 |
| Chu KM et al. | A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. | 1998 | Am. J. Gastroenterol. | pmid:9732921 |
| Lamouliatte H et al. | Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. | 1998 | Am. J. Gastroenterol. | pmid:9732938 |
| Chiba N | Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. | 1996 | Am. J. Gastroenterol. | pmid:8855737 |
| Dohil R et al. | Effective 2-wk therapy for Helicobacter pylori disease in children. | 1997 | Am. J. Gastroenterol. | pmid:9040199 |
| Lerang F et al. | Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? | 1997 | Am. J. Gastroenterol. | pmid:9040200 |
| Odaka T et al. | Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. | 2002 | Am. J. Gastroenterol. | pmid:11922552 |
| Chey WD et al. | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. | 1997 | Am. J. Gastroenterol. | pmid:9317068 |
| Ozmen MM and Johnson CD | Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? | 1995 | Am. J. Gastroenterol. | pmid:7661197 |
| Kim CG et al. | Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. | 2008 | Am. J. Gastroenterol. | pmid:17714557 |
| Savarino V et al. | New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. | 1995 | Am. J. Gastroenterol. | pmid:7717343 |
| Sirimontaporn N et al. | Ten-day sequential therapy of Helicobacter pylori infection in Thailand. | 2010 | Am. J. Gastroenterol. | pmid:20010919 |
| Basu PP et al. | A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. | 2011 | Am. J. Gastroenterol. | pmid:21989146 |
| Moayyedi P and Malfertheiner P | Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? | 2009 | Am. J. Gastroenterol. | pmid:19956122 |
| Zullo A et al. | A quintuple therapy for H. pylori eradication. | 2007 | Am. J. Gastroenterol. | pmid:17958765 |
| Hasegawa T et al. | Image of the month: Disseminated Nontuberculous Mycobacteriosis. | 2015 | Am. J. Gastroenterol. | pmid:26673493 |
| Schwartz H et al. | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. | 1998 | Am. J. Gastroenterol. | pmid:9576452 |
| de Boer WA et al. | Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. | 1998 | Am. J. Gastroenterol. | pmid:9672338 |
| Vakil N and Fennerty MB | Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. | 1996 | Am. J. Gastroenterol. | pmid:8607487 |
| Treiber G | The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. | 1996 | Am. J. Gastroenterol. | pmid:8607488 |
| Shaheen N and Grimm IS | Fulminant hepatic failure associated with clarithromycin. | 1996 | Am. J. Gastroenterol. | pmid:8607519 |
| Vakil N | Helicobacter pylori treatment: a practical approach. | 2006 | Am. J. Gastroenterol. | pmid:16542285 |
| Jarbol DE et al. | Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. | 2006 | Am. J. Gastroenterol. | pmid:16771937 |
| Bytzer P | Management of the dyspeptic patient: anything goes? | 2006 | Am. J. Gastroenterol. | pmid:16771938 |
| Manes G et al. | Eradication of Helicobacter pylori and dosages of esomeprazole. | 2006 | Am. J. Gastroenterol. | pmid:16771971 |
| Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| van der Wouden EJ et al. | One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. | 1998 | Am. J. Gastroenterol. | pmid:9707042 |
| Laine L et al. | Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. | 2000 | Am. J. Gastroenterol. | pmid:11151867 |
| Parasakthi N and Goh KL | Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. | 1995 | Am. J. Gastroenterol. | pmid:7872306 |
| Nam SY et al. | Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. | 2010 | Am. J. Gastroenterol. | pmid:20571493 |
| Veldhuyzen van Zanten S et al. | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. | 2003 | Am. J. Gastroenterol. | pmid:14499772 |